NASDAQ: AMGNAMGEN INC Stock
$245.37+2.28 (+0.94%)
Updated Jun 24, 2022
AMGN Price
$245.37
Fair Value Price
$257.22
Market Cap
$131.08B
52 Week Low
$198.64
52 Week High
$258.45
P/E
24.1x
P/B
143.1x
P/S
5.04x
PEG
0.9x
Dividend Yield
3.02%
Revenue
$26.32B
Earnings
$5.72B
Gross Margin
75.2%
Operating Margin
29.36%
Profit Margin
21.7%
Debt to Equity
63.62
Operating Cash Flow
$9B
Beta
0.73
Next Earnings
Aug 1, 2022
Ex-Dividend
N/A
Next Dividend
N/A
AMGN Overview
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMGN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMGN ($245.37) is undervalued by 4.61% relative to our estimate of its Fair Value price of $257.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMGN ($245.37) is not significantly undervalued (4.61%) relative to our estimate of its Fair Value price of $257.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMGN ($245.37) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AMGN due diligence checks available for Premium users.
AMGN News
Valuation
AMGN fair value
Fair Value of AMGN stock based on Discounted Cash Flow (DCF)
Price
$245.37
Fair Value
$257.22
Undervalued by
4.61%
AMGN ($245.37) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMGN ($245.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMGN ($245.37) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
24.1x
Industry
9.02x
Market
20.48x
AMGN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AMGN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
AMGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
143.1x
Industry
5.43x
AMGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMGN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AMGN is good value based... subscribe to Premium to read more.
PEG Value Valuation
AMGN's financial health
Profit margin
Revenue
$6.2B
Net Income
$1.5B
Profit Margin
23.7%
AMGN's Earnings (EBIT) of $7.73B... subscribe to Premium to read more.
Interest Coverage Financials
AMGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.2B
Liabilities
$58.3B
Debt to equity
63.62
AMGN's short-term assets ($18.52B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMGN's long-term liabilities ($45.39B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMGN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AMGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.2B
Investing
-$111.0M
Financing
-$3.5B
AMGN's operating cash flow ($9.32B)... subscribe to Premium to read more.
Debt Coverage Financials
AMGN vs General Drug Manufacturer Stocks
AMGEN Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.